A biosensing device and methods for detecting the SARS-CoV-2 virus sequence in a biological fluid. The device includes an interdigitated electrode, a supporting flexible membrane and an electrode material that is disposed on the interdigitated electrode and supporting flexible membrane. The electrode material is selected from (i) two-dimensional and layered MXenes and (2) printable graphene, wherein the electrode material is functionalized with ssDNA primers specific to the SARS-CoV-2 virus sequence to be detected. The device also includes a sensor that reads an electrical resistance change across the interdigitated electrode after a target DNA sequence is applied to the electrode material.

Provided herein are methods of preparing a detectable antibody-antibody binding agent aggregate, the method comprising: (a) contacting a biological sample with an antibody binding agent, wherein the antibody binding agent comprises an antibody binding antigen and a detectable label, wherein the antibody binding agent binds an antibody in the biological sample; (b) adding an aggregating agent to the biological sample, wherein the aggregating agent binds to the antibody and forms an antibody-antibody binding agent aggregate; and (c) detecting a signal from the detectable label of the antibody binding agent associated with the antibody-antibody binding agent aggregate, thereby preparing a detectable antibody-antibody binding agent aggregate.

Methods, compositions, and kits for analyzing viral particles. In an exemplary method of analyzing viral particles, capsids of the viral particles may be tagged with a tag. Subsamples of a sample containing the viral particles may be formed. Each subsample of only a subset of the subsamples may include at least one of the viral particles. One or more targets may be amplified from a genome of the viral particles. Tag-related data, and amplification data for the one or more targets, may be collected from the subsamples. In some examples, a capsid occupancy of the viral particles may be determined in a calibration-free approach using the collected data without quantification of the viral particles or capsids thereof.

The field of the invention generally relates to sample collection, for example of a sample being an exhaled breath. In particular, an integrated device is disclosed herein comprising a silicon chip for sampling particulate matter from a sample and for analysis, preferably by a protocol using thermocycling, of the particulate matter as collected from the sample. Further, point-of-care (PoC) and self-use analysis systems compatible with the integrated device, and methods related to sample collection and/or analysis using the same, are also disclosed.

Provided herein are methods of detecting pathogen antibodies, such as a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in samples. Related devices, kits, reaction mixtures, and systems are also provided.

The present invention relates to a homogeneous, time resolved, Förster resonance energy transfer (TR-FRET)-based method for detection of SARS-CoV-2, SARS CoV-1, and MERS-CoV antibodies in a patient fluid sample.

A method for providing variable function medical tests, comprising providing by a mobile device application a plurality of selectable medical test functions, receiving information from the mobile device application regarding test results from a test performed using a testing device, wherein the testing device includes an alignment target disposed on the testing device and a plurality of immunoassay test strips receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing by the server the single value to a control value stored on the server, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

Provided herein are methods of detecting a pathogen, such as a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), in aerosol samples. Related devices, kits, systems, and computer program products are also provided.

Provided are methods of detecting a biomolecule of interest in a sample. In certain embodiments, the methods comprise contacting the sample with a biolayer interferometry (BLI) sensor, the BLI sensor comprising a capture antigen specific for the biomolecule affixed to the BLI sensor, wherein a wavelength shift detected by the BLI sensor indicates the presence of the biomolecule of interest in the sample. The methods may further comprise contacting the BLI sensor with a detecting reagent (e.g., an antibody or the like) specific for the biomolecule of interest, where the detecting reagent is conjugated to a colloidal gold particle or other signal enhancing molecule. In certain embodiments, the biomolecule of interest is an antibody specific for a viral antigen, e.g., a SARS-CoV-2 antigen-specific antibody, or the like. Also provided are BLI sensors and kits that find use, e.g., in practicing the methods of the present disclosure.

A liquid biopsy system and method for the detection of SARS-CoV-2 antibodies in bodily fluids is described. In particular, the system is suitable for detecting SARS-CoV-2 antibodies in a saliva sample of a subject.